Analysis Teva Pharmaceuticals Gets a Coronavirus Boost, but It Won’t Last Long
Patients stocking up on drugs lifted sales in the first quarter. The current quarter may be weaker, but Israeli drugmaker remains bullish for the year
Teva Pharmaceutical
Teva Claims Restructuring Has Stabilized Business
Company sees strong growth in migraine treatment Ajovy and Huntington’s treatment Austedo in 2020
Analysis Israeli Drug Giant Teva Stock Price Stutters as Legal Cloud Darkens
An advantageous deal to get itself out of the opioid scandal brought investors back – but the storm is gaining strength again
U.S. Federal Prosecutors Launch Criminal Probe of Opioid Makers, Report Says
Shares of Israel's Teva, other drug companies drop after grand-jury subpoenas from the U.S. attorney’s office in the Eastern District of New York
N.Y. Regulator Notifies Opioid Makers of Enforcement Action
The New York State Department of Financial Services has sent letters to around 23 opioid manufacturers and distributors
Teva Pharm Nudges Up Earnings Forecast, Names New CFO
A drop in profit was expected, but despite the optimism, Teva is nowhere near out of the opioid scandal
Teva’s Proposed Court Settlement Could Cost It Just Pennies on the Dollar
Company announced value of donated medicine based on list price, which does not account for routine, significant discounts
Teva Shares Rally on Opioid Settlement, but Analysts Have Doubts
Tentative $23 billion deal announced on Monday could be boost for financially troubled Israeli drug maker. But deal remains short on details, and not all the plaintiffs may sign on
Teva, Three Other Drugmakers Reach Settlement as U.S. Opioid Trial Set to Begin
Last-minute $260 million legal settlement averts first federal trial over companies' role in opioid addiction epidemic
After Opioids Affair, Sackler Money Complicates Donation Policies for Museums
While Tate museums and Guggenheim cut ties with the family, the Smithsonian, Metropolitan Museum of Art and Harvard are struggling due to contractual obligations
Teva Shares Drop in Tel Aviv Wednesday After Purdue Opioid Settlement Offer
Israeli drug company sank 9.6% on Nasdaq on Tuesday
J&J Liable for $572m in U.S. Opioid Epidemic Trial, but Teva, Other Drug Makers' Shares Surge
In first case to go to trial out of thousands of lawsuits, payment ordered by an Oklahoma judge is 'much lower than had been feared,' says healthcare strategist
Teva Shares Plunge After Rating Warning, Bernie Sanders-led Probe
Moody's puts Negative outlook on drug makers debt ■ Stock drops to 10.51 % at $6.30
Teva Shares Crash as Settlement Plan for Opioid Suits in the U.S. Is Proposed
Israeli drug giant's shares dropped more than 13% on the Tel Aviv Stock Exchange the same day the company's chief financial officer announced his resignation
Teva to Get $50m Back in Bribery Case Settlement
Payment is to cover part of penalties drug maker paid to U.S., Israel
Teva, Other Drug Makers Negligent in Vetting Opioid Orders, Court Papers Allege
Troubling disclosures likely to pressure pharmaceutical companies to settle suits quickly, a development Israel’s Teva will try to avoid
Teva’s Sinking Bond Price Poses Insolvency Threat
Yields have risen sharply, complicating drug maker’s plans to recycle debt
Teva Shares Close Down 8.6% in Tel Aviv; Morgan Stanley Warns They Could Plummet Further
Analyst David Risinger of Morgan Stanley lowered his future price for the stock on the Nasdaq from $16 to $6; it closed in Tel Aviv Monday at $8.49
Oklahoma Judge Approves Teva’s $85 Million Opioid Settlement
Deal came just days before the drugmaker was set to face trial for its alleged role in helping to fuel epidemic
Israel's Teva Plunges on Opioid Settlement, Bezeq on Write-off Woes
Investors fear the drugmaker will pay billions for its alleged role in the U.S. opioid epidemic, while the communications giant has been stung by losses at its satellite TV unit
Teva to Pay Oklahoma $85 Million in Opioid Lawsuit
Settlement reached days before company was set to face trial
Billionaire Buffett Has Probably Taken $213 Million Loss on His Teva Stock
Legendary investor had 3.9% stake in drug marker at end of first quarter
Analysis Teva’s Legal Woes Threaten Its Ability to Repay Heavy Debt
The drug maker not only faces price-fixing allegations in the U.S. but also is a party to a suit on opiod abuse
Teva Loses Status as Biggest Firm on TASE as Israelis Sue Too
Israeli institutional investors seeking class action in the U.S. estimate that price-fixing inflated Teva's profits by $2.3 billion
Analysis The Price-fixing Claims Look Worse for Teva Than They Really Are
It’s a nasty business but the financial impact on Teva is containable and the bigger picture for the troubled drug maker is looking brighter
40 U.S. States Sue Teva, Other Drugmakers for 'Multi-billion Dollar Fraud on the American People'
'We all wonder why the prices for generic prescription drugs are so expensive – this is a big reason why,' Connecticut attorney general says, alleging price-fixing conspiracy
Teva Tumbles at Tel Aviv Opening Following Massive U.S. Lawsuit
40 U.S. states sue Teva, other drugmakers for 'multi-billion dollar fraud on the american people'
Israel's Teva Sees Sharp Rise in Revenue Next Year Boosted by New Migraine Drug
Israeli drug maker reports better-than-expected quarterly rules, but shares post a drop anyhow
Israel's Teva Halts Testing Alternative Use for Migraine Drug
The world’s largest generic drug company was counting on the drug Ajovy to help revive it after 2018 debt crisis
Israel's Largest Venture Capital Firm to Focus on Health Care
Named aMoon2 and led by Marius Nacht and Dr. Yair Schindel, the company has $660 million to invest